SCHEMBL1359129

SCHEMBL1359129

O=c1c(O)c(-c2ncc(Cc3ccc(F)cc3)s2)nc2sc(CN3CCOCC3)cn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 2/20 0.38
SLC2A1 P11166 1/20 0.37
TSHR P16473 1/20 0.37
SLC2A3 P11169 1/20 0.37
SLC2A4 P14672 1/20 0.37
GRM2 Q14416 1/20 0.37
CNR2 P34972 3/20 0.36
MAPK14 Q16539 1/20 0.35
CNR1 P21554 1/20 0.35
GAA P10253 2/20 0.35
OPRK1 P41145 1/20 0.35
CCR6 P51684 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359882 0.91 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL12138802 0.91 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL1361053 0.89 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL12138821 0.88 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL823471 0.87 SLC2A1 (0.44) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL12138811 0.85 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL12138836 0.85 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL1360623 0.84 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9ASLC2A1
SCHEMBL1359078 0.84 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPC1RAB9ATSHR
SCHEMBL12138962 0.83 NPC1 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US claimed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP claimed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
US-8426405-B2 Thiazopyrimidinones and uses thereof AVEXA LIMITED (AU) 2013-04-23 US disclosed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP disclosed
EP-2247601-B1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2013-04-10 EP disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-11-17 US disclosed
WO-2010000030-A1 THIAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281861-A1 THIAZOPYRIMIDINONES AND USES THEREOF TPMT, CYP2C19, CYP3A5 SMN1; SMN2 1592/4885ALDH1A1 124/4885NPC1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.